Quantcast

Pharmazz’s PMZ-1620 could become the first-in-class therapy to treat cerebral ischemic stroke

Pharmazz’s PMZ-1620 could become the first-in-class therapy to treat cerebral ischemic stroke, the company said in a statement, through an endothelin (ETB receptor) based mechanism of action, of anti-apoptosis and stimulation of hidden stem cells to repair the damaged brain by formation of new neurons and blood vessels.

Read more